Your leading global event focused solely on AI in drug discovery is returning in 2025.
With deeper insights into target identification and target validation, and advanced sessions on AI-driven drug design, the event will now be adding dedicated content tracks for AI infrastructure, as well as a leadership forum on partnerships and business models and further expansion of the “women in AI” series. With new case studies, interactive workshops, and expanded networking opportunities, this year’s summit will be bigger and more impactful than ever.
Join us in Boston on November 18-20, 2025, as we push the boundaries of AI-driven drug discovery. We can’t wait to see you there!
2025 Featured Speakers

Peter Clark
VP, Computational Drug Design
Novo Nordisk

Peter Clark
VP, Computational Drug Design
Novo Nordisk

Claire Zhao
Associate Director, AI/ML & Quantitative & Digital Sciences
PFIZER

Claire Zhao
Associate Director, AI/ML & Quantitative & Digital Sciences
PFIZER

Zoran Krunic
Principal Product Manager
Amgen

Zoran Krunic
Principal Product Manager
Amgen
Since joining Amgen R&D in 2018, Zoran Krunic has been at the forefront of applying Machine Learning to enhance patient outcomes and streamline clinical trial enrollment processes, utilizing comprehensive Electronic Health Records and clinical datasets. His pioneering work in the Quantum Machine Learning space, in collaboration with IBM's Quantum team, has been instrumental in integrating machine learning with quantum computing through IBM’s Qiskit platform.
Prior to his tenure at Amgen, Zoran developed Machine Learning algorithms at Optum to predict hardware and software failures within complex enterprise architectures. He has a strong background in data engineering and systems development, having contributed significantly to large-scale projects at renowned organizations such as Capital Group and ARCO Petroleum.
In his current full and part-time endeavors, Zoran is leading the efforts in embracing generative AI technologies, with a particular focus on OpenAI's GPT and Anthropic's Claude-2 models. His work is focused on prompt engineering and its application to code generation, advanced document analysis, and process management, with a commitment to ethical AI practices and data privacy.
A recognized voice in quantum computing circles, Zoran is a regular presenter at industry conferences and has served on numerous panels discussing the integration of quantum computing and generative AI within the Health Sciences sector.
With a Master of Science in Electrical Engineering & Computer Science, Zoran continues to explore and contribute to the evolving relationship between quantum computing and artificial intelligence, fostering groundbreaking advancements in healthcare technology.

Chirag Sacher
Director, Portfolio Innovation
Novartis

Chirag Sacher
Director, Portfolio Innovation
Novartis

Ari Allyn-Feuer
Director, AI Product
GSK

Ari Allyn-Feuer
Director, AI Product
GSK

Mark Adams
Venture Capital Partner
Two Bear Capital

Mark Adams
Venture Capital Partner
Two Bear Capital

Petrina Kamya
Global Head, AI Platforms, VP Insilico Medicine & President
Insilico Medicine

Petrina Kamya
Global Head, AI Platforms, VP Insilico Medicine & President
Insilico Medicine

Arvind Rao
Associate Professor, Computational Medicine & Bioinformatics
University of Michigan

Arvind Rao
Associate Professor, Computational Medicine & Bioinformatics
University of Michigan

Jackie Hunter
CEO
OI Pharma Partners

Jackie Hunter
CEO
OI Pharma Partners

Zhiyong (Sean) Xie
VP & Head, AI & Data Science
Xellarbio

Zhiyong (Sean) Xie
VP & Head, AI & Data Science
Xellarbio

Adam Root
VP & Head, Protein Sciences
Generate Biomedicines

Adam Root
VP & Head, Protein Sciences
Generate Biomedicines

Ethan Pickering
Head, Data Science & ML Research
Bayer

Ethan Pickering
Head, Data Science & ML Research
Bayer
Industry Experts
Industry Leading Speakers
Main Event Days
Pre-Day Workshop
Who Attends






Attendees Include...


















































Balancing AI's Promises and Challenges
AI is transforming drug discovery, showing promise in preclinical research, but clinical success is still a challenge.

The Importance of Data Quality and Sharing for AI
High-quality, diverse data is essential for effective AI. Data-sharing ensures inclusivity and accuracy.

The Power of Collaboration in AI-Driven Drug Development
Cross-functional collaboration is crucial for AI-driven drugdevelopment to tackle challenges and maximize AI's potential.

Quantum Computing and AI in Drug Discovery
Quantum computing and autonomous systems, combined with AI, are unlocking new possibilities in drug discovery.